Description: TAGRIX (Osimertinib) is the 1st and only drug of its kind approved by USFDA for the treatment of epidermal growth factor receptor (EGFR) positive Non- Small Cell Lung Cancer (NSCLC) patient with T790M mutation.
TAGRIX is indicated for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC).
Product Name : Tagrix
Generic Name : Osimertinib
Formulation : Tablet
Available Pack size : 30’s
Strengths : 80mg
Manufacturer: Beacon Pharmaceuticals
Tag: Tagrix, Osimartinib